Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well cediranib maleate works in treating patients with
malignant mesothelioma that cannot be removed by surgery. Cediranib maleate may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking
blood flow to the tumor